Possible participation of advanced glycation end products in the pathogenesis of osteoporosis in diabetic patients
- 1 January 2005
- journal article
- Published by Elsevier in Medical Hypotheses
- Vol. 65 (6) , 1013-1015
- https://doi.org/10.1016/j.mehy.2005.07.017
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Education, Culture, Sports, Science and Technology
This publication has 19 references indexed in Scilit:
- Advanced Glycation End-Products Attenuate Human Mesenchymal Stem Cells and Prevent Cognate Differentiation Into Adipose Tissue, Cartilage, and BoneJournal of Bone and Mineral Research, 2005
- Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture riskDiabetologia, 2005
- Osteoporosis: Incidence, Prevention, and Treatment of the Silent KillerNursing Clinics of North America, 2005
- Alternative routes for the formation of glyceraldehyde-derived AGEs (TAGE) in vivoMedical Hypotheses, 2004
- TAGE (toxic AGEs) hypothesis in various chronic diseasesMedical Hypotheses, 2004
- Diabetes Mellitus: Does it Affect Bone?Calcified Tissue International, 2003
- Advanced glycation end-products pentosidine and N -carboxymethyllysine are elevated in serum of patients with osteoporosisRheumatology, 2003
- Osteoporosis and DiabetesCurrent Diabetes Reports, 2003
- Pyridoxamine, an Inhibitor of Advanced Glycation Reactions, Also Inhibits Advanced Lipoxidation ReactionsPublished by Elsevier ,2000
- Diabetic bone diseaseCalcified Tissue International, 1991